help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on December 21, 2004
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1093
A more recent version of this article appeared on March 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/3/1856    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bevan, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bevan, J. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

The Anti-Turmoral Effects of Somatostatin Analog Therapy in Acromegaly

John S. Bevan MD, FRCPEd*

Department of Endocrinology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, Scotland, UK

* To whom correspondence should be addressed. E-mail: j.s.bevan{at}arh.grampian.scot.nhs.uk.

Somatostatin analogs are the mainstay of medical therapy for acromegaly. Suppression of growth hormone (GH) hypersecretion, lowering of insulin-like growth factor 1 (IGF-1) production, and control of symptoms are established benefits of therapy. In addition, clinically significant tumor shrinkage has been seen in a number of studies, particularly in patients undergoing primary medical therapy. This review summarizes current knowledge of the effects of somatostatin analogs on tumor size and cellular morphology, and examines the available data on predictors of tumor shrinkage.
Key words: Acromegaly • somatostatin analog • octreotide • lanreotide • pituitary tumor • microadenoma • macroadenoma




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar
Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization
Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, R. Pivonello, R. S. Auriemma, M. Galdiero, S. Savastano, L. F. S. Grasso, and G. Lombardi
Growth Hormone-Secreting Tumor Shrinkage after 3 Months of Octreotide-Long-Acting Release Therapy Predicts the Response at 12 Months
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3436 - 3442.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Beckers
Does Preoperative Somatostatin Analog Treatment Improve Surgical Cure Rates in Acromegaly? A New Look at an Old Question
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2975 - 2977.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, R. Pivonello, M. Galderisi, P. Cappabianca, R. S. Auriemma, M. Galdiero, L. M. Cavallo, F. Esposito, and G. Lombardi
Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2639 - 2646.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. F Taboada, R. M Luque, L. V. Neto, E. d. O Machado, B. C Sbaffi, R. C Domingues, J. B Marcondes, L. M C Chimelli, R. Fontes, P. Niemeyer, et al.
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Eur. J. Endocrinol., March 1, 2008; 158(3): 295 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
C. L Ronchi, E. Rizzo, A. G Lania, R. Pivonello, S. Grottoli, A. Colao, E. Ghigo, A. Spada, M. Arosio, and P. Beck-Peccoz
Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal
Eur. J. Endocrinol., January 1, 2008; 158(1): 19 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Colao, R. Pivonello, R. S Auriemma, M. Galdiero, S. Savastano, and G. Lombardi
Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly
Eur. J. Endocrinol., November 1, 2007; 157(5): 579 - 587.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. A. Nolan, H. A. Schmid, and A. Levy
Octreotide and the Novel Multireceptor Ligand Somatostatin Receptor Agonist Pasireotide (SOM230) Block the Adrenalectomy-Induced Increase in Mitotic Activity in Male Rat Anterior Pituitary
Endocrinology, June 1, 2007; 148(6): 2821 - 2827.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Resmini, P. Dadati, J.-L. Ravetti, G. Zona, R. Spaziante, A. Saveanu, P. Jaquet, M. D. Culler, F. Bianchi, A. Rebora, et al.
Rapid Pituitary Tumor Shrinkage with Dissociation between Antiproliferative and Antisecretory Effects of a Long-Acting Octreotide in an Acromegalic Patient
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1592 - 1599.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. C. Zatelli, M. R. Ambrosio, M. Bondanelli, and E. C d. Uberti
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S29 - S35.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. F Taboada, R. M Luque, W. Bastos, R. F C Guimaraes, J. B Marcondes, L. M C Chimelli, R. Fontes, P. J P Mata, P. N. Filho, D. P Carvalho, et al.
Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas
Eur. J. Endocrinol., January 1, 2007; 156(1): 65 - 74.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Melmed
Acromegaly
N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. L. Batista, X. Zhang, R. Gejman, P. J. Ansell, Y. Zhou, S. A. Johnson, B. Swearingen, E. T. Hedley-Whyte, C. A. Stratakis, and A. Klibanski
The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4482 - 4488.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. Castillo, D. Giacomini, M. Paez-Pereda, J. Stalla, M. Labeur, M. Theodoropoulou, F. Holsboer, A. B. Grossman, G. K. Stalla, and E. Arzt
Retinoic Acid as a Novel Medical Therapy for Cushing's Disease in Dogs
Endocrinology, September 1, 2006; 147(9): 4438 - 4444.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
E. Hubina, A. M Nanzer, M. R Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M. R. Terreni, S. Khalaf, S. Jordan, et al.
Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
Eur. J. Endocrinol., August 1, 2006; 155(2): 371 - 379.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, R. Pivonello, R. S. Auriemma, F. Briganti, M. Galdiero, F. Tortora, F. Caranci, S. Cirillo, and G. Lombardi
Predictors of Tumor Shrinkage after Primary Therapy with Somatostatin Analogs in Acromegaly: A Prospective Study in 99 Patients
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2112 - 2118.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio, S. Lodrini, P. Doneda, L. Cortesi, and G. Pagani
Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1397 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, R. Attanasio, R. Pivonello, P. Cappabianca, L. M. Cavallo, G. Lasio, A. Lodrini, G. Lombardi, and R. Cozzi
Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 85 - 92.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhayana, G. L. Booth, S. L. Asa, K. Kovacs, and S. Ezzat
The Implication of Somatotroph Adenoma Phenotype to Somatostatin Analog Responsiveness in Acromegaly
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6290 - 6295.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G M Besser, P Burman, and A F Daly
Predictors and rates of treatment-resistant tumor growth in acromegaly
Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society